Mengjie Yang

NHC Key Laboratory Of Biosafety
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Mucosal boosting of chimpanzee adenovirus-vectored vaccine encoding SARS-CoV-2 RBD-heterodimer provides robust protection in mice.

Mucosal boosting of chimpanzee adenovirus-vectored vaccine encoding SARS-CoV-2 RBD-heterodimer provides robust protection in mice.

Journal: mBio

Published: July 21, 2026

T cell immune evasion by SARS-CoV-2 JN.1 escapees targeting two cytotoxic T cell epitope hotspots.

T cell immune evasion by SARS-CoV-2 JN.1 escapees targeting two cytotoxic T cell epitope hotspots.

Journal: Nature immunology

Published: July 09, 2024

The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.

The safety, immunogenicity, and efficacy of heterologous boosting with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: a randomized, open-label, active-controlled phase 3 trial.

Journal: Emerging microbes & infections

Published: June 11, 2024

Long-lasting humoral and cellular memory immunity to vaccinia virus Tiantan provides pre-existing immunity against mpox virus in Chinese population.

Long-lasting humoral and cellular memory immunity to vaccinia virus Tiantan provides pre-existing immunity against mpox virus in Chinese population.

Journal: Cell reports

Published: June 29, 2023

Stability of SARS-CoV-2 and persistence of viral nucleic acids on common foods and widely used packaging material surfaces.

Stability of SARS-CoV-2 and persistence of viral nucleic acids on common foods and widely used packaging material surfaces.

Journal: Journal of medical virology

Published: March 13, 2023

Inactivated vaccine fueled adaptive immune responses to Omicron in 2-year COVID-19 convalescents.

Inactivated vaccine fueled adaptive immune responses to Omicron in 2-year COVID-19 convalescents.

Journal: Journal of medical virology

Published: March 10, 2023

A novel mRNA vaccine, SYS6006, against SARS-CoV-2.

A novel mRNA vaccine, SYS6006, against SARS-CoV-2.

Journal: Frontiers in immunology

Published: September 23, 2022

Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial.

Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial.

Journal: Signal transduction and targeted therapy

Published: September 14, 2022

Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial.

Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial.

Journal: Nature communications

Published: February 17, 2022

Surveillance of SARS-CoV-2 at the Huanan Seafood Market.

Surveillance of SARS-CoV-2 at the Huanan Seafood Market.

Journal: Nature

Published: February 17, 2022

Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial.

Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial.

Journal: Signal transduction and targeted therapy

Published: January 12, 2022

One-Year Sustained Cellular and Humoral Immunities in Coronavirus Disease 2019 (COVID-19) Convalescents.

One-Year Sustained Cellular and Humoral Immunities in Coronavirus Disease 2019 (COVID-19) Convalescents.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: August 27, 2021

Showing 1-12 of 21

Last Updated: 09/26/2026